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 Fibroblast growth factors (FGFs) are a family of growth factors which includes 
twenty three proteins. FGFs work as modulators for various cellular activities like mitosis, 
differentiation and survival. Among the FGF family, human fibroblast growth factor-1 
(hFGF-1), which is also known as acidic fibroblast growth factor, is a potent angiogenic 
agent, involved in the formation of new blood vessels in various tissues. hFGF-1 is 
regarded as a prototype of the FGF family. It serves as one of the potential targets in 
tumor inhibition and obesity due to its involvement in new blood vessel formation in 
cancerous regions and adipose tissues. In general, FGFs exert their action by binding to 
heparin, forming FGF-heparin complex, which can then bind to fibroblast growth factor 
receptors (FGFRs). Inhibition of FGF dependent signal transduction by heparin mimicking 
compounds has shown promising results in control and treatment of tumor growth. 
Naturally occurring glycoside called phloridzin found to have anticancer property. 
Phloridzin (2-glucoside of phloretin) has structural resemblance to heparin; it is a natural 
antioxidant, widely known for its antidiabetic activity, besides controlling tumor growth.  
Phloridzin can mimic heparin and compete with it for FGF binding. This binding can be 
agonistic or antagonistic in nature on FGF signal transduction.  In the present study, we 
investigated the molecular level interaction between phloridzin and hFGF-1 using various 
biophysical techniques like steady state fluorescence, limited trypsin digestion and 
protein-NMR spectroscopy. 
x 
  
hFGF-1 needed for the study was expressed in recombinant Escherichia coli cells.  
The expressed protein was then purified using heparin sepharose affinity chromatography. 
Both expression and purification were monitored using SDS-PAGE (sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis). Conformational stability of purified hFGF-1 
was assessed through steady state fluorescence. Purified hFGF-1 is in, its native, properly 
folded conformation. 
           Interaction studies, such as thermal unfolding and limited trypsin digestion were 
performed to assess the thermal stability and solvent accessibility of hFGF-1 in the 
presence of phloridzin respectively. It was found from interaction studies that hFGF-1 in 
the presence of phloridzin shown increased thermal stability and increased resistance 
against trypsin digestion. In order to locate the sites of interaction on hFGF-1 surface, a 
protein-NMR study was performed. Exact sites of interaction of phloridzin on hFGF-1 
surface were found.  In future, isothermal titration calorimetry will be performed to 
determine kinetics of the enthalpy change and dissociation constant of phloridzin-hFGF-1 
interaction. In vivo studies will also be performed after completion of in vitro studies, 
which will give an insight about possibility of phloridzin and hFGF-1 interaction under 
physiological condition
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1. INTRODUCTION 
Fibroblast Growth Factors Family: 
            FGF family is a group of twenty three closely related polypeptides which are 
encoded by twenty three different FGF genes. The first FGF was found in pituitary 
extracts by H.A. Armelin in 1970. Its proliferative property was first reported in 1974; in 
later years, other members of the FGF family were identified. Among 23 proteins, the 
best characterized prototypes are FGF-1 and FGF-2.1-4 FGFs play a vital role in 
vertebrate embryonic and fetal development and also in physiological and pathological 
conditions of adults.5, 6 All FGFs show high affinity towards heparin and bind with it to 
form a FGF-heparin complex. Formation of the FGF-heparin complex is a prerequisite 
for FGF functional activity.  FGFs elicit their response by activating cell-surface tyrosine 
kinase receptors which are known as fibroblast growth factor receptors (FGFRs).7, 8            
            In structural aspects, FGFs share an internal 120 amino acid core domain 
containing 28 highly conserved and 6 identical amino acids. The molecular weight of 
FGFs ranges from 17 to 34 kDa. In humans, based on phylogenetic analysis, FGFs are 
grouped into seven distinct families1. Invertebrates were also found to contain FGF genes 
and transcripts, whereas no evidence was found about FGFs existence in unicellular 
organisms.9 Functional diversity and increase in number of FGFs occurred during the 
metazoan evolution.2, 10, 11 In terms of activity, studies have shown that in vitro cell 
cultures, FGFs can stimulate the mitosis, cell differentiation, migration and cell survival, 
while in vivo; they regulate wide array of cellular functions such as angiogenesis, wound 
healing, and bone regeneration etc.12 
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Functions of FGFs in Organism Development: 
            FGFs play a key regulatory role in multicellular organism development; they are 
involved right from the process of implantation to the growth of offspring.13 In early 
development stages of fetus, FGFs act as inducers of mesoderm and are involved in 
regulation of cell migration in gastrulation process (the formation of three germ layers).14 
Studies have shown that inhibition of FGF signaling during early development blocks 
mesoderm formation and causes posterior gastrulation defects.14 In addition, FGFs act as 
mitogenic agents for most of the cell arrays of mesodermal and endodermal origin.14 
Strict temporal and spatial patterns were observed in FGF expression during embryonic 
differentiation and organ development. An especially crucial role of FGFs was found in 
formation of the lungs and the limbs. FGFs play a significant role in alveolar formation, 
branching of trachea; in limb development, FGFs induces formation of an organizer 
called the apical ectodermal ridge (AER) which further guides limb development and cell 
death.15-18 FGFs also play key regulatory role in central nervous system development and 
midbrain formation. Central nervous system development is a multistep process; recent 
studies suggested that FGF signaling is required at the very earliest stages of neural 
induction to the establishment of appropriate connectivity.15-18 In mid brain development, 
FGFs induce cell proliferation in formation of midbrain-hindbrain boundary (MHB).19, 20 
Biological Functions of FGFs in Adult Organisms:  
            In adult organisms, FGFs play a major role in wound healing, tissue repair, 
angiogenesis and steps involved in homeostatic regulation (detailed description of 
biological functions is under subheading, therapeutic implications of FGFs, page number: 
7).12, 22-23 FGFs are also identified as factors involved in some pathological conditions, 
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particularly neoplasia, diabetic retinopathy, rheumatoid arthritis, atherosclerosis and 
tumor growth.25-29  
Different FGF’s Binding Surfaces and FGF Tyrosine Kinase Receptors: 
            FGFs elicit their response by binding and activating high affinity cell surface 
receptors known as FGF-receptors which have an intrinsic tyrosine kinase activity. Upon 
binding of FGF to FGFRs, dimerization of receptor takes place which is essential to 
activate the associated tyrosine kinase domain through auto-phosphorylation.8, 30 In 
addition to FGFR binding sites, most FGFs also contain sites with high affinity for 
heparin and heparan sulphate proteoglycans (HSPGs). Heparin and HSPGs, which 
present on the cell surface and extracellular matrix, binds with FGFs, protect them 
against proteases and thermal denaturation and also regulate binding and activation of 
FGFRs.31   
            The FGFR family includes five closely related genes, which encodes for five 
different FGF receptors. Among five, four receptors contain a trans-membrane tyrosine 
kinase domain, and the fifth receptor of the gene family lacks the tyrosine kinase domain. 
The four trans-membrane tyrosine kinase receptors share a common structure which is 
composed of three extracellular Ig-like domains (D1, D2, D3), an unique acidic region 
(acid box), a transmembrane domain, and a well conserved tyrosine split domain (Figure 
1), they share up to 70% identity.32 Structural and functional dissimilarities among 
different FGFRs are generated through mechanisms based on alternative splicing of 
FGFR encoding mRNA and alternate promoter activity resulting in receptor isoforms.7 
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Figure 1: Schematic structure of FGFR, showing, extracellular domain which contains a 
signal peptide domain, three ig like domains (D1, D2, D3), a transmembrane region and 
an internal tyrosine kinase domain.24           
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Figure 2: FGF signal transduction. Formation of the FGF: FGFR: HSPG signalling 
complex causes the activation of the intracellular kinase domains and the phosphorylation 
of tyrosines on the FGFRs. FRS2 interacts with the phosphorylated tyrosines and is 
phosphorylated itself. FRS2 then activates the adaptor protein Grb2 that associates with 
SOS which in turn activates Ras. Ras is a small GTP binding protein that activates Raf, 
which activates MEK which in turn activates MAPK (ERK). FRS2 activity also activates 
phosphoinositide-3 kinase, which activates AKT/PKB. PLCγ binds the activated FGFR 
by its SH2 domain and then generates inositol-1, 4, 5-trisphosphate and DAG from 
phosphotidylinositol-4, 5-diphosphate resulting in the activation of protein kinase C.24 
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Heparan Sulphate Proteoglycans (HSPGs) as a Low Affinity FGF Cell Surface 
Receptors: 
            In addition to binding to FGFRs, FGFs also bind to Heparin or HSPGs; which act 
as low affinity FGF cell surface receptors. Function of low affinity cell surface receptors 
is to regulate FGF binding and FGFRs activation. Heparin binding mediates dimerization 
of hFGF-1 and stabilization of FGF, high and low affinity receptor complex which is 
very essential for FGF signal transduction.34 Heparin binding is unique to FGFs, as other 
growth factors do not require heparin/HSPG binding in order to elicit specific response.34 
Both heparin and HSPG belong to a glycosaminoglycan class of proteoglycans. HSPGs 
consist of core protein and several other carbohydrate moieties. The carbohydrate 
moieties of these glycosaminoglycans are highly sulfated, which impart negative charge 
to the HSPGs34. HSPGs are found more abundantly on the cell surface and extra cellular 
matrix and provide more binding sites per cell.34 
Binding Interaction among FGFs, FGFRs and Low Affinity Cell Surface Receptors:  
            Dimerization of FGFRs takes place when FGFs bind with them, followed by auto-
phosphorylation of intracellular tyrosine residues of receptors. The key event in the 
activation process is the auto-phosphorylation of tyrosine residues in the activating loop 
of tyrosine kinase, which leads to increased activity of the receptor kinase.36 Other 
phosphokinases on the tyrosine kinase serve as binding sites for recruitment and 
activation of downstream signaling molecules (Figure 2). As a consequence of these 
events, activated FGFRs transduce signals to nucleus via a cascade of signaling 
molecules including Ras/mitogen-activated protein kinase (MAPK), phosphoinositide 3-
kinase (PI3K)/Akt, phospholipase Cγ (PLCγ ) and p38 MAPK.36,37   
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            Apart from binding to the FGF-heparin complex, FGFRs juxtamembrane domain 
serve as constitutive binding sites for docking proteins such as FRS2β and FRS2α. It was 
known from the studies that FRS2α works as a major mediator in FGFR signaling. Upon 
FGF stimulation, docking proteins gets phosphorylated and induces growth factor 
receptor bound protein 2 (Grb 2), which is necessary for activating Ras/MAPK signaling 
pathway.38  
Therapeutic Implications of FGF Mediated Biological Processes: 
Angiogenesis:  
           Angiogenesis is a complex, multi-step phenomenon that involves formation of 
new blood vessels from pre-existing blood vessels.47 Multiple pro and anti-angiogenic 
factors regulate the process of angiogenesis. Among those factors, the best recognized 
ones are vascular endothelial growth factors (VEGFs), transforming growth factors α and 
β (TGFα and β), platelet-derived growth factor (PDGF), angiopoetins, FGF-1 and FGF-2. 
FGF family members, especially FGF-1 and FGF-2 play a very significant role in all 
steps of angiogenesis.47 In different cell lines, such as endothelial cells, fibroblasts, and 
tumor cells, FGF-1, FGF-2 and FGF-4 have been showed to induce urokinase-type 
plasminogen activator (uPA) through Ras/Raf-1/MEK/Erk1, 2/JunD pathways.48 uPa is 
responsible for dissolving extracellular matrix (ECM), surrounding the existing vessels 
by activating the metalloproteinases (MMPs), which are necessary for degradation and 
remodeling of ECM. FGF-1 and FGF-2 have shown to directly induce MMPs production 
in target cells.49, 50  FGF-1, FGF-2 and FGF-4 also play a vital role in migration and 
proliferation of endothelial cells.50 At present, recombinant FGFs are widely used as a 
therapeutic approach to treat insufficient angiogenesis.  
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Wound Healing: 
            A wound is a sharp injury that specifically damages the dermis. To re-
epithelialize the wound, various growth factors play an important role in attracting the 
basal and supra basal keratinocytes to the site of injury, which release uPA and MMPs to 
dissolve the clot formed on the surface of the wound. As FGF-1, FGF-2 and FGF-4 are 
involved in uPA production, they play a vital role in wound healing.50 In diseases like 
diabetes, symptoms such as delayed wound healing and insufficient granulation tissue 
formation are observed, which can be attributed to the defects involving fibroblast 
function. Exogenous administration of recombinant FGFs is believed to be a therapeutic 
strategy to elevate the process of wound healing.50 
            Bone Fracture Healing: 
                        Bone regeneration in adult organisms depends on the regenerative capacity of 
periosteum, which is a specialized connective tissue forming a thin fibrous membrane 
firmly anchored to the bone. The periosteum is the main regenerative tissue in bone 
fracture healing. FGF-1, FGF-2 and platelet-derived growth factor (PDGF) are secreted. 
At the site of bone fractures, FGF-1 and FGF-2 stimulates the proliferation of 
periosteum-derived cells during the early stages of bone repair.51 The most important 
factors involved in healing bone fractures are VEGF, PDGF and FGF-2. However, 
recent in vivo studies showed that FGF-1 alone can have ability to induce de novo 
formation of bone tissue. 
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Cancer: 
            Therapeutic properties of FGFs are beneficial in curing certain disorders 
pertaining to angiogenesis. However, at supra-physiological concentrations, FGFs show 
oncogenic potential. Therefore, care should be taken when FGFs are used for therapeutic 
purpose. FGFs by virtue of their properties as a mitogenic and angiogenic agent in certain 
circumstances, may contribute to onset or a faster progression of cancer. The mechanism 
by which FGFs causes oncogenesis can either be autocrine or paracrine in nature. Over 
expression of FGFs is the cause in certain tumors, whereas in others, FGFRs were over-
expressed and responsible for uncontrolled growth.52, 53 
Human Fibroblast Growth Factor-1(hFGF-1): 
            The hFGF-1 is a powerful mitogenic agent, which plays an important role in 
stimulation of DNA synthesis and proliferation of a wide array of cell lines including 
fibroblasts, endothelial cells, smooth muscle cells, myoblasts, chondrocytes and glial 
cells.12 It is being investigated as a pro-angiogenic drug candidate for treating diseases 
like peripheral artery disease, wound healing in diabetic ulcers and non-treatable 
coronary occlusions.54, 55 The hFGF-1 exerts action through variety of signaling 
transduction processes, which are described in previous paragraphs.  
            The hFGF-1 is a non-glycosylated polypeptide made up of 154 amino acid 
residues.12 Its structure consists of 12 β strands arranged antiparallel in β-trefoil motif, 
which is one of the fundamental protein super folds (Figure 3).56, 57 Among the 6 double-
stranded β hairpins, three forms upper β barrel structure, and three form a lower 
triangular array respectively forming a cap on the barrel at one end.57  The alignment of 
secondary structures gives a pseudo three fold internal symmetry to hFGF-1. 
10 
 
 
Figure 3: Spatial structure of hFGF-1(Based on crystal structure).56 
            The hFGF-1 is relatively a low stability protein with its denaturation temperature 
at around 40 °C. Chaotropic agents like urea and guanidium chloride, can denature 
hFGF-1.58-61 Both thermal and chemical denaturation follows a binary state model 
involving two phases in denaturation process.  Heparin and its derivatives strongly 
stabilize hFGF-1 against thermal and chemical denaturation because anionic ligands 
stabilize the rigidity of the whole hFGF-1 molecule, especially in the regions of receptors 
interaction. Therefore, in presence of poly-anions, hFGF-1 shows increased stability 
against denaturant.61 For instance, at elevated temperature of 30 ºC and in presence of 
heparin, hFGF-1 stability is increased by 14-20 ºC.62-65 
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            Phloridzin: 
            Phloridzin, which is also known by phlorizin, phlorrhizin, phlorhizin or 
phlorizoside, is a glucoside of phloretin; it belongs to a chemical class of 
dihydrochalcones (Figure 4). Its structure is closely resembles to flavonoid precursors i.e. 
chalcones, and it is one of the the major phenolic glucoside found in Malus domestica 
(apple trees).66 Since its isolation from the bark of apple trees in 1835 by De Koninck, 
phloridzin has attracted immense scientific interest as a pharmaceutical and human 
physiology research tool.67    
 
Figure 4: Molecular structure of phloridzin (2-Glucoside of phloretin)  
Chemical name of phloridzin: 1-[2, 4-dihydroxy-6-[(2S, 3R, 4R, 5S, 6R)-3, 4, 5-
trihydroxy-6-hydroxymethyl) tetraHydropyron-2-yl) oxy-phenyl]-3-[4-hydroxyphenyl) 
propan-1-one. 
            Phloridzin is a competitive inhibitor of sodium glucose transporter1 and 2 
(SGLT1 and SGLT2), which are present on the surface of the proximal convoluted tube 
of nephron and on the intestinal mucosa of small intestine. Phloridzin reduces renal as 
well as abdominal glucose transport, lowering the amount of glucose in the blood, 
therefore assisting in controlling glucose levels in type-I diabetic patients. Recent studies 
on phloridzin and its derivatives focused on biological functions such as lipid 
12 
 
peroxidation, inhibition of tumor growth, and enhancement of memory and life 
extension.68-70  
Why to Study Interaction between hFGF-1 and Phloridzin? 
                        During the last 30 years, enormous advances have been made with regard to 
understand various mechanisms that are involved in carcinogenesis. There is now enough 
evidence that a tumor requires blood supply for growth and metastasis.71, 72 Therefore, 
role of FGFs in angiogenesis led to intensive efforts to find agents which can inhibit FGF 
mediated angiogenesis.73  
           In control and treatment of cancer growth, inhibition of FGF dependent signal 
transduction by heparin mimicking compounds has shown promising results. Some of the 
heparin mimicking compounds such as suramin, carrageenans, and pentosan polysulfate  
were reported to have an inhibitory effect on the activity of FGFs.75-77  
            Phloridzin, apart from its anti-diabetic activity also acts as an anticancer agent.68-
70 It is still unclear how phloridzin is involved in inhibition of cancer. In our present 
study, an attempt was made to understand interaction between hFGF-1 and phloridzin. 
Since hFGF-1 is a potent angiogenic agent in normal and cancerous tissues.  
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2. MATERIALS 
Microorganism: Recombinant Escherichia coli  
Transformation of hFGF-1gene into E.coli:  hFGF-1 (GenBank # X59065) cDNA was 
made using standard procedures and it was cloned into a pJExpress414 vector (DNA2.0) 
and transformed into BL21 (DE3) E. coli cells for the overexpression.79, 82 The gene 
sequences were optimized using DNA2.0 codon bias algorithm to maximize the yield of 
the proteins, prior to the cloning. 
Table 1. Chemicals used: 
Chemical Name Purchased from 
Acryl amide EMD chemicals 
Ammonium chloride EMD chemicals 
Ammonium per sulfate EMD chemicals 
Ammonium sulfate EMD chemicals 
Ampicillin EMD chemicals 
Bromophenol blue Allied Chemical 
Calcium chloride EMD chemicals 
Chloramphenicol Cal Biochem 
Dextrose EMD chemicals 
Glacial acetic acid EMD chemicals 
Glycerol EMD chemicals 
Glycine EMD chemicals 
Isopropyl β-D-1-thiogalactopyranoside EMD chemicals 
Lorea broth Navagen 
Monobasic and dibasic  sodium phosphate EMD chemicals 
Magnesium chloride EMD chemicals 
Mercaptoethanol J.T. Baker 
Methanol EMD chemicals 
14 
 
N15 labeled ammonium chloride EMD chemicals 
Phloridzin Sigma aldrich 
Potassium sulfate EMD chemicals 
Potassium di-hydrogen phosphate EMD chemicals 
Potassium hydrogen phosphate EMD chemicals 
R 250 Dye Fisher Biotech 
Riboflavin EMD chemicals 
Sodium azide EMD chemicals 
Sodium chloride J.T. Baker 
Sodium dodecyl sulfate J.T. Baker 
Temed EMD chemicals 
Thiamine Acros Organic 
Tris Base Cal Biochem 
Tri-chloro acetic acid J.T. Baker 
Urea J.T. Baker 
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Preparation of Buffers:  
0.5 M Phosphate Buffer Preparation (500 mL): 
0.5 M  NaH2PO4 . 2H2O  (Monobasic) (FW:156 g ): 30 g of monobasic sodium phosphate 
was weighed and dissolved  in nano pure water  (~ 400 mL). The total volume was made 
up to 500 mL with nano pure water using graduate cylinder. 
0.5 M  Na2HPO4 .12H2O (Dibasic) (FW:358): 35.5 g of dibasic sodium phosphate was 
weighed and dissolved  in nano pure water  (~ 400 mL), and the total volume was made 
up to 500 mL with nano pure water using graduated cylinder. 
0.5 M phosphate buffer was made by mixing 50 mL of buffer 1(monobasic) with 450 mL 
of buffer 2 (dibasic). The final pH of the solution was measured with a pH meter and the 
pH was adjusted to 7.2 using acid/base. Contents were then transferred to glass bottle, 
labeled and stored at room temperature.  
Use: To make buffers for purification and dialysis. 
10 mM Phosphate Buffer (1 L): From previously prepared 0.5 M phosphate buffer, 20 
mL was measured and poured into a 1L graduated cylinder. Nano pure water was added 
to the cylinder up to 1L volume. The contents are mixed well and transferred to a glass 
bottle. To the buffer, 1 mL of sodium azide was added. The final pH of the solution was 
measured with a pH meter and the pH was adjusted to 7.2 using acid/base. Then, contents 
were transferred to a glass bottle, labeled and stored at room temperature. 
Use: To make buffers for purification and dialysis. 
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5 M Sodium Chloride Solution (500 mL): 146 g of sodium chloride was weighed and 
dissolved in ~450 mL of nano pure water. The solution was made up to 500 mL using 
nano pure water. Then, contents were transferred to glass bottle, labeled and stored at 
room temperature. 
Use: To make elution buffers 
0.8 M NaCl in 10 mM Phosphate Buffer (500 mL):  In a 1 L conical flask, 80 mL of 5 
M sodium chloride was mixed with ~ 400 mL of 10 mM phosphate buffer. Total volume 
was made up to 500 mL with 10 mM phosphate buffer using a graduated cylinder. The 
solution pH was measured with a pH meter and the pH was adjusted to 7.2 using 
acid/base. Then, contents were transferred to glass bottle, labeled and stored at room 
temperature. 
Use: To remove other proteins while purification 
1.5 M NaCl in 10 mM Phosphate Buffer (1 L): In a 1 L conical flask,150 mL of 5 M 
sodium chloride solution was mixed with ~300 mL 10 mM phosphate buffer.  The total 
volume was made up to 500 mL with 10 mM phosphate buffer using a graduated 
cylinder. The solution pH was measured with a pH meter and the pH was adjusted to 7.2 
using acid/base. Then, contents were transferred to glass bottle, labeled and stored at 
room temperature. 
1 M Sodium Azide Solution (100 mL): 6.5 g of sodium azide was weighed and 
dissolved in ~80 mL of nano pure water, volume was measured with graduated cylinder 
and solution volume was made up to 100 mL using nano pure water. Then, the contents 
were transferred to glass bottle, labeled and stored in refrigerator. 
Use: To prevent contamination in buffers. 
17 
 
Dialysis Buffer (4 L): In a 4 L conical flask, 80 mL of 5 M sodium chloride (100 mM), 
80 mL of 0.5 M of phosphate buffer (10 mM), 26.4 g of ammonium sulfate (50 mM) and 
4 mL of 1 M sodium azide were mixed. To the contents, ~3.5 L nano pure water was 
added. Solution volume was measured with graduated cylinder and it was made up to 4 L 
using nano pure water. The solution pH was measured with a pH meter and the pH was 
adjusted to 7.2 using acid/base. Then, contents were transferred to glass bottle, labeled 
and stored at room temperature. 
Use: Desalting 1.5 M hFGF-1 elution fractions 
10 X Phosphate Buffer Saline (1 L): In a conical flask, 42.89 g of Na2HPO4 .12H2O, 
5.51 g of NaH2PO4 .2H2O, and 87.66 g of NaCl were dissolved in ~600 mL of nano pure 
water. Volume of the solution was measured with graduated cylinder and it was made up 
to 1 L with nano pure water. The solution pH was measured with a pH meter and the pH 
was adjusted to 7.2 using acid/base. Contents were then transferred to glass bottle, 
labeled and stored at room temperature. 
Use: To make buffers by dilution 
1 X Phosphate Buffer Saline: In a conical flask, 100 mL of 10 X PBS was diluted with 
nano pure water to 1L. The solution pH was measured with a pH meter and the pH was 
adjusted to 7.2 using acid/base. 
Use: To re-suspend the bacterial pellet after expression and centrifugation 
Solutions for SDS-PAGE: 
Tris (Tris hydroxyl methyl) Amino Methane [pH 8.8]: To prepare this solution 24.22 
g of tris base was weighed and dissolved in ~150 mL of nano pure water, and the pH of 
the solution was then adjusted to 8.8. The volume of contents was measured with 
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graduated cylinder and it was made up to 200 mL using nanopure water. Once again the 
pH of the solution was measured and adjusted to 8.8. Contents were then transferred to 
glass bottle and stored in refrigerator. 
Use: To make polyacrylamide gels, maintains pH in prepared gels 
Tris (Tris hydroxyl methyl) Amino Methane [pH 6.8]: To prepare this solution 24.22 
g of tris base was weighed and dissolved in ~150 mL of nano pure water, pH of the 
solution was then adjusted to 8.8. Volume of contents was measured with graduated 
cylinder and it was made up to 200 mL using nanopure water. Once again the pH of the 
solution was measured and adjusted to 8.8. Contents were then transferred to glass bottle, 
labeled and stored in refrigerator. 
Use: To make polyacrylamide gels, maintains pH in prepared gels 
10% Sodium Dodecyl Sulfate: 4 g of sodium dodecyl sulphate (SDS) was weighed and 
dissolved in 40 mL of nano pure water and a vigorous vortex was done to dissolve the 
SDS. The contents volume was measured with graduate cylinder and it was made up to 
50 mL using nano pure water. Contents were then transferred to glass bottle, labeled and 
stored at room temperature. 
Use: To make polyacrylamide gels, it imparts charge on loaded proteins.  
10% Ammonium per Sulfate: 1 g of ammonium per sulfate was weighed and dissolved 
in 10 mL of nano pure water. The contents were then transferred to glass bottle, labeled 
and stored in refrigerator. 
Use: Fasten the gel formation by producing free radicles. 
Staining Buffer: In a 1L conical flask, 2.5 g of R 250, 450 mL of methanol and 100 mL 
of glacial acetic acid were mixed. To the flask ~400 mL of nano pure water was added, 
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contents were mixed thoroughly. The volume of the contents measured with graduated 
cylinder and it was made up to 1L using nano pure water. Then, the flask was labeled and 
stored at room temperature. 
Use: To stain the gel for electrophoresis. 
Distaining Buffer: In a 1L conical flask, 150 mL of methanol, 75 mL of glacial acetic 
acid and 775 mL of nano pure water were mixed. Then, flask was labeled and stored at 
room temperature. 
Use: To destain gel after staining. 
Stock Running Buffer: In a 1L conical flask, 30.8 g of tris base, 144 g of glycine and 10 
g of sodium dodecyl sulfate and ~ 500 mL of nano pure water was added and contents 
were mixed thoroughly using magnetic stirrer. The volume of the solution was measured 
and it was made up to 1 L using nano pure water. Then, the flask was labeled and stored 
at room temperature. 
Use: To make electrolyte for SDS-PAGE. 
Running Buffer for SDS-PAGE: In a 1L conical flask 930 mL of nano pure water, 70 
mL of stock running buffer were mixed. Then, the flask was labeled and stored at room 
temperature. 
Use: As an electrolyte solution in SDS-PAGE. 
0.1% Bromophenol Blue: 50 mg of bromophenol blue was weighed and dissolved in 50 
mL of nano pure water; then the contents were transferred into a 100 mL glass bottle, 
labeled and stored at room temperature. 
Use: To make loading dye for SDS-PAGE. 
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Stock Loading Dye: It was prepared by mixing 0.6 mL of tris base (pH 6.8), 1 mL of 
glycerol and 2 mL of 10% SDS and 5.4 mL of nano pure water. Solution was stored at 
room temperature. 
Use: To make loading dye for SDS-PAGE. 
2X Loading Dye: 500 µL of 2x loading dye was prepared by mixing 475 µL of stock 
loading dye with  25 µL of mercaptoethanol. 
Use: It imparts color to the protein loaded in gel. 
150% Tri Chloro Acetic Acid: 15 g of tri-chloro acetic acid was dissolved in 10 mL of 
nano pure water, and then the contents were labeled and stored at room temperature. 
Use: For processing protein samples for SDS-PAGE. 
8 M Urea: 9.6 g of urea was weighed and dissolved in ~15 mL of nano pure water and 
then the contents were made up to 20 mL using nano pure water then labeled and stored 
at room temperature.  
Use: For processing protein samples for SDS-PAGE. 
Minimal Media Preparation:  
500 mL of minimal media was prepared by mixing following components, 13 g of 
potassium dihydrogen phosphate (KH2PO4),10 g of potassium hydrogen phosphate 
(K2HPO4), 9 g of sodium hydrogen phosphate (Na2HPO4), 2.4 g of potassium sulfate 
(K2SO4), 400 mg of dextrose, 50 mg of 
15N ammonium chloride (NH4Cl),10 µL of 1M 
calcium chloride (CaCl2),1 mL of 1M magnesium chloride (MgCl2), 500 µL of 5 mg/mL 
thiamine, 68 µL of riboflavin, 100 µL of 50 mg/mL ampicillin  and 100 µL of 34 mg/mL 
chloramphenicol.  All components were mixed with ~900 mL of nano pure water and 
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volume was measured with graduated cylinder, the final volume was made up to 1 L 
using nano pure water. The contents were then labeled and stored in refrigerator. 
Use: To express 15N labeled hFGF-1 in recombinant E.coli culture. 
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3. METHODS 
Expression and solubility of hFGF-1:  
            The E.coli cells transformed with pJExpress414 vector cloned with hFGF-1 insert 
were available in the laboratory.  Cultivation of  E.coli  cells was carried out  in 500 mL 
of lorea broth (LB) media at 37 ºC. The absorbance of growing culture was monitored at 
regular intervals of time at 600 nm. When absorbance had reached about 0.6 at 600 nm 
(In general, at ~ 0.6 absorbance, cells are in an actively multiplying state), a few mL of 
culture was collected and labeled as un-induced, then an inducer IPTG (Isopropyl β-D-1-
thiogalactopyranoside) (0.5 mg/mL) was added to the culture to induce hFGF-1 
production in the growing cells. After adding inducer, the culture was incubated for 
another 6 hours followed by which the cells were harvested and lysed by sonication with 
pulse amplitude of 35% for 30 min.  Produced lysate was used for analyzing expression 
and solubility of hFGF-1 through SDS-PAGE.  Protein samples of both un-induced and 
induced cultures were precipitated with 150 % (w/v) tri-chloro acetic acid, and the 
precipitates were incubated for 10 min at 4 ºC temperature (Figure 5).78 After incubation, 
the precipitates were centrifuged for at 12,000 rpm for 3 min. Precipitates were then 
washed with 200 µL of acetone; the suspension was pelleted again by centrifuging the 
samples at 12, 000 rpm for 3 min.   Finally the settled pellets were dissolved in 15 µL of 
8M urea, which was followed by addition of 10 µL of loading buffer (Figure 5).  From 
the above solution of 25 µL of sample, 20 µL of each sample was added to gel. Then 
SDS-PAGE was carried out for one hour to separate the proteins from the loaded sample 
according to their molecular size. 
 
23 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
             
Figure 5: Flow chart representing individual steps involved in expression of hFGF-1 in 
recombinant E.Coli and subsequent SDS-PAGE analysis. 
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            Purification of hFGF-1:  
            Purification was carried out using heparin affinity chromatography to separate 
hFGF-1 from other proteins. The bacterial lysate was centrifuged at 15000 rpm for 20 
min. The supernatant was collected in a separate container and the pellet was discarded. 
The supernatant was loaded onto a heparin sepharose affinity column and incubated for 
60 min. undesired proteins and other materials such as lipids from the loaded lysate were 
removed from the column by running wash buffer (10 mM phosphate buffer). 
Purification was then carried out over NaCl gradient (from 0 to 1.5M). Collected 
fractions were analyzed by SDS-PAGE (Figure 6).  From the SDS-PAGE results, the 
fractions with more concentration of protein were subjected to desalting (with dialysis 
buffer which contain 10 mM phosphate buffer,  100 mM NaCl and 50 mM ammonium 
sulfate, pH 7.2) of eluted fractions. The purity of the final protein sample was further 
assessed using SDS-PAGE by comparing the protein marker and hFGF-1 bands on the 
gel. 
 Steady State Fluorescence Measurements:  
            Thermodynamic stability of hFGF-1 was assessed from the thermal de-
natauration experiments. These fluorescence experiments were carried out using 
PerkinElmer Spectro-fluorometer. The excitation and emission wavelengths were set at 
280 and 394 nm respectively and band width for excitation and emission were set at 2.5 
nm and 10 nm respectively. Intrinsic fluorescence experiments were performed using 50 
µM of hFGF-1. Thermal denaturation experiments were carried out using 1:10 ratio of 
hFGF-1 and phloridzin in 10 mM phosphate buffer (pH 7.2) containing 100 mM NaCl.  
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Figure 6: Flow chart representing individual steps involved purification of hFGF-1 and 
subsequent SDS-PAGE analysis. 
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Intrinsic fluorescence spectra were obtained from 20 °C to 74 °C with 3 °C interval.  
Temperature requirements were controlled using Fisher thermo-scientific temperature 
controller.  
Proteolytic Digestion:  
            Protection of hFGF-1 by phloridzin against the action of trypsin was evaluated by 
limited trypsin digestion experiment. Trypsin to hFGF-1in 1:1 ratio and excess of 
phloridzin were used. Temperature for the digestion experiment was maintained at 35 ºC. 
Trypsin digestion was carried out for 70 min; samples of digestion were collected at 
every 10 min interval. After the collection of samples, SDS-PAGE analysis was 
conducted to evaluate the activity of trypsin on the hFGF-1 in presence and absence of 
phloridzin. The extent of cleavage was measured from the intensity of 16 kDa band on 
the gel, for the control and phloridzin treatment. The hFGF-1 band which was not treated 
with trypsin was considered as a positive control for 100% protection against proteolytic 
digestion. 
15N  Labeled Human FGF-1 expression and purification:  
                  1H-15N HSQC-NMR is a widely used experiment in protein NMR studies. For 
proteins to be active for 2D NMR, two different hetero nuclear atoms should be present 
in amino acid backbone . Hydrogen is one heteronuclear atom and other can be isotope of 
either carbon or nitrogen with odd mass number (i.e. 13C or 15N). Typically, 15N labeled 
hFGF-1 proteins are produced by expressing the proteins in cells grown in 15N labeled 
media. To produce 15N labeled hFGF-1, 600 mL of minimal media was prepared by 
dissolving dextrose, 15N NH4Cl, MgCl2, CaCl2, thiamine, vitamin A, ampicillin and 
chloramphenicol in nano pure water. Ampicillin and chloramphenicol inhibit the growth 
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of other bacteria except recombinant E.coli (which is resistant to ampicillin and 
chloramphenicol). For preculture 100 mL of media was used, in which bacterial cells 
were grown for 16 hours. A similar procedure to of normal hFGF-1 purification, was 
followed for purifying N15 labeled hFGF-1 
Hetero nuclear Sequence Quantum Coherence (HSQC) NMR:  
            NMR experiments were performed on a Bruker Avance-700 MHz spectrometer 
(cryoprobe). The concentration of the protein sample was 1 mM in 95% H2O and 5% 
D2O and it was prepared in 10 mM phosphate buffer containing 100 mM sodium chloride 
(pH 7.2). All NMR data were acquired at 25 ± 0.5 °C. In total, 10 different spectra were 
collected with different molar concentrations of phloridzin. 
4. RESULTS AND DISCUSSION 
Expression and Purification of hFGF-1:  
            Expression and purification of hFGF-1 was monitored through SDS-PAGE. Most 
of the expressed protein is in soluble form (Figure 5). The bacterial lysate was purified 
using heparin sepharose affinity chromatography.  
            FGFs have a high affinity towards heparin, due to electrostatic interaction 
between positive charge on the FGFs and negative charge on the heparin. Unbound 
proteins, which do not show any affinity towards the heparin, can be easily removed by 
running wash buffer (10 mM phosphate buffer). After elution of undesired proteins with 
wash buffers, FGFs can be eluted by varying salt concentrations or salt gradient in 
increasing order.  
            The hFGF-1 was purified over a NaCl gradient (from 0 to 1.5 M NaCl). Wash 
buffer (10 mM phosphate buffer) was run through the column to remove the unbound 
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proteins. At high concentrations, the sodium ions (1.5 M) replace the hFGF-1 which is 
bounded to heparin in the column during the purification. The eluted fractions with high 
amount of hFGF-1 were assessed with SDS-PAGE, which yielded single intense band 
corresponding to a molecular mass of ~16 kDa (Figure 7). The fraction which showed 
intense band was subjected to desalting (100 mM NaCl). Quantification of hFGF-1 was 
done using UV-Vis spectroscopy. The concentration of hFGF-1 was estimated based on 
its extinction coefficient value (∑280 = 17,420 M
−1 cm−1) calculated from amino acid 
sequence of hFGF-1.79 The final concentration of hFGF-1 produced was found to be 32 
mg/L of bacterial culture. The protein sample was labeled and stored at -20 ºC. 
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Figure 7: SDS-PAGE depicting expression and purification of hFGF-1 from Escherichia 
coli, Lane M represents protein molecular weight marker; lane 1 represents un-induced 
sample; lane 2 represents Induced sample; lane 3 represents soluble fraction; lane 4 
represents insoluble fraction;  lane 5 represents flow through, lane 6 depicts protein bands 
contained in fraction eluted in 10 mM phosphate buffer; lane 7 depicts protein bands 
contained in fraction eluted in 10 mM phosphate buffer containing 0.8 M NaCl; lanes 8-
11  depicts protein bands contained in fraction eluted in 10 mM phosphate buffer 
containing 1.5 M NaCl; lane 12 represents protein bands contained in fraction eluted in 
10 mM phosphate. 
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Protein-Ligand Interaction Studies: 
            Thermal denaturation of hFGF-1 in the presence of phloridzin: 
            The hFGF-1 contains 8 tyrosine residues and a single, well conserved tryptophan 
residue at 121 position.78 When the protein is in native form, fluorescence spectra are 
dominated by the tyrosine emission peak at 308 nm. The fluorescence from tryptophan 
residue is completely quenched in the native state. The quenching of tryptophan 
fluorescence is due to presence of lysine and histidine residues side chains in spatial 
proximity of the tryptophan residue (Figure 8A).78, 80 However, this quenching effect is 
not observed in the denatured state of protein in 8M urea (Figure 8A). In denatured states 
tryptophan fluorescence at 350 nm dominates the fluorescence spectra, these spectral 
features are ideal for analyzing the effect of denaturant on the conformational stability of 
hFGF-1.78 The I308/I350 ratio (I: fluorescence intensity at a given wavelength) is a useful 
tool to analyze the conformational stability of protein as a function of temperature. A 
higher value (~3) indicates more native like, properly folded structure, whereas a lower 
value (~1) indicates altered structure.80 
            In order to assess the conformational stability of hFGF-1 upon phloridzin binding, 
equilibrium thermal denaturation studies were conducted (Figure 8B). Intrinsic 
fluorescence spectra were obtained from 20 °C to 74 °C at 3 °C interval and I308/I350 
values were calculated and plotted as a function of temperature. In comparison,  melting 
temperature(Tm) (The temperature at which 50% of the protein molecules are in native 
state) of the hFGF-1 was increased by about 3 °C (from 56 °C to 59 °C), meaning, 
conformational stability of hFGF-1 is enhanced upon binding to phloridzin. 
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Figure 8: (A) Graph representing intrinsic fluorescence spectra of hFGF-1, excited at 
280 nm showing maximum peak intensity at 308 nm and the ratio of 308 nm/350 nm is 
approximately 3 which means the protein is in native condition and properly folded state, 
In the denatured form the maximum peak intensity was observed at 350 nm and the ratio 
308 nm/350 nm is approximately 1. (B)  Graph representing the thermal unfolding of 
hFGF-1 in the absence and in the presence of phloridzin.  The Tm value of the thermal 
induced unfolding of hFGF-1 estimated from the fluorescence experiment is 56 ⁰C in the 
absence and 59 ⁰C in the presence phloridzin. The ligand (phloridzin) binds to the hFGF-
1 and stabilizes the protein about 3 ºC. 
 
 
 
 
 
 
 
400 
1 
 
 
0.8 
 
 
 
0.6 
 
 
0.4 
 
 
 
0.2 
 
 
  
RelatiR
P
ro
te
in
 F
ra
ct
io
n 
U
nf
ol
d 
          23   29   35    41    47   53   59   65   71   
Temperature in °C 
R
el
at
iv
e 
F
lu
or
es
ce
nc
e 
In
te
ns
it
y 
1000 
800 
600 
 
200 
0 
300 350 400 450 
Wavelength in nm 
 
Denatured 
Protein 
 
 Native 
protein 
 
A B 
 
hFGF-1 
hFGF-1 
with 
Phloridzin 
32 
 
Limited Proteolytic Digestion:  
            Limited proteolytic digestion is a useful technique to evaluate the protein- ligand 
interactions. Proteases are the proteins which cleave the other proteins at specific amino acid 
residues. The main principle behind this technique is that, when a ligand strongly binds with 
a protein substrate, it potentially masks the protease cleaving sites on protein substrate.78  The 
subtle differences in protein cleavage patterns produced by proteases (between protein bound 
with ligand and free protein) could be easily analyzed using SDS-PAGE. Limited proteolytic 
digestion is mainly governed by three factors stereochemistry, protein substrate accessibility 
and specificity of proteolytic enzyme (Schematic, Figure 9).78  For this study, trypsin was 
used to probe the phloridzin and hFGF-1 binding since hFGF-1 is rich in arginine and lysine 
residues and trypsin has specifically cleave at the sites of arginine and lysine in the 
polypeptide. Time dependent trypsin digestion (in free and phloridzin bound) was monitored 
through SDS-PAGE. The degree of hFGF-1 digestion by trypsin, was measured in 
comparison to intensity of the 16 kDa band (after coomassie blue staining) corresponding to 
undigested hFGF-1(Figure 10). The percent of un-cleaved hFGF-1 was measured using a 
scanning densitometer and graph of percent of uncleaved was plotted as a function of time. 
The results confirmed that rate of cleaving of hFGF-1was slowed down in the presence of 
phloridzin (Figure 11). From the results of SDS-PAGE analysis of trypsin digests of hFGF-1 
in the presence and absence of phlordzin, it was demonstrated that in the presence of 
phloridzin, hFGF-1 is more resistant to the trypsin digestion. It is because of phloridzin 
binding to hFGF-1 and sterically restricting the trypsin cleavage sites in the drug binding site. 
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Figure 9: Schematic representing limited trypsin digestion of a polypeptide, trypsin 
specifically cleaves the peptide bonds of arginine and lysine in polypeptide. 
 
 
 
 
 
 
 
Figure 10: Proteolytic digestion with protease called trypsin, of hFGF-1 in the presence 
and (A) absence of the phloridzin (B), the rate of digestion has been slowed, when the 
hFGF-1 treated with phloridzin compared to the hFGF-1 alone. Numbers in the above 
figure represents time in min corresponding to the sample collected. The above result 
indicates that the phloridzin protecting the hFGF-1 against proteolytic digestion. 
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Figure 11: Graphical representation showing percentage of undigested hFGF-1 alone 
(orange) and in the presence of phloridzin (green). The percentage of undigested hFGF-1 
was estimated from the intensity of the coomassie blue stained band in the 
polyacrylamide gel.  
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Protein- NMR: 
            Protein NMR experiments are versatile techniques to depict the protein ligand 
interface at an atomic level resolution. They are also useful tools in finding stoichiometry 
and binding affinity of protein-ligand interactions. Among different protein NMR 
experiments, 1H-15N HSQC experiment is the most frequently recorded experiment. 1H-
15N HSQC spectrum serves as a fingerprint of the backbone conformation of proteins.80 
Every protein has unique spectra based on its conformation. Each cross peak in the 
spectra represents amine groups of amino acid residues. Therefore, sites of ligand binding 
could be easily identified by chemical shift perturbations or disappearance of certain 
cross peaks (Schematic, Figure 12).81 15N labeled hFGF-1 were produced by cultivating 
E.Coli cells in 15N rich culture media (Figure13). In this experiment, we mapped putative 
binding sites of phloridzin on hFGF-1 on the basis of spectra obtained at various drug: 
protein molar ratios (Figure 14). 1H-15N HSQC spectra of 10 different combinations of 
drug: protein molar ratios (phloridzin: hFGF-1 0.2:1 to 2:1 with 0.2 mM increments in 
titration) were acquired and the individual spectra were overlapped with free hFGF-1 1H-
15N HSQC spectrum. From the results, it was revealed that only few cross peaks have 
been disappeared even at high concentrations of phloridzin. Gly34, Tyr61, Tyr70, Gly77, 
Ala 109, Asp 146 cross peaks were the one that changed positions in the overlapped 
spectra, and Tyr 129 cross peak disappeared in the overlapped spectra. We conclude that 
these cross peaks could be the putative binding sites of the phloridzin on the hFGF-1 
surface. 
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Figure 12: Schematic representing sequence of steps in performing 2D-NMR for 15N 
labeled hFGF-1. 
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Figure 13: SDS-PAGE depicting expression and purification of N15 labeled hFGF-1 
from E.coli, lane M represents protein molecular weight marker; lane 1 represents un-
induced sample; lane 2 represents Induced sample; lane 3 represents flow through; lane 4 
depicts protein bands contained in fraction eluted in 10 mM phosphate buffer; lane 5 
depicts protein bands contained in fraction eluted in 10 mM phosphate buffer containing 
0.8 M NaCl; lanes 6-9  depicts protein bands contained in fraction eluted in 10 mM 
phosphate buffer containing 1.5 M NaCl; lane 10 represents protein bands contained in 
fraction eluted in 10 mM phosphate.   
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Figure 14: Overlap of the HSQC spectra of hFGF-1 in the absence (purple) and presence 
of phloridzin (green).The yellow boxed areas represent selected cross-peaks of residues 
that disappear in the presence of phloridzin. The blue boxed areas represent selected cross-
peaks of residues that perturbed/shifted in the presence of phloridzin.  
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5. CONCLUSION 
The prototype of the FGF family, hFGF-1 was selected for studying molecular level 
interactions with phloridzin. hFGF-1 was expressed in recombinant E.coli and purified 
from bacterial lysate using heparin sepharose affinity chromatography. The purified 
protein was analyzed with steady state fluorescence for its conformational stability. It 
was confirmed from the results that produced protein was in native conformation. 
Interaction studies such as, thermal unfolding and proteolytic digestion of hFGF-1 in the 
presence phloridzin were conducted. Control experiments without the use of ligand were 
also carried out in order to evaluate the changes in the stability of protein in the presence 
of ligand. In the thermal unfolding experiment, intrinsic fluorescence spectra of hFGF-1 
were obtained from 20 ºC to72 ºC at 3 ºC interval. Melting temperature (Tm) was used as 
a parameter to compare the thermal stability. The Tm of hFGF-1 in the presence of 
phloridzin was increased by about 3 ºC.  In limited trypsin digestion experiment, where 
the hFGF-1 was subjected digestion with protease called trypsin, hFGF-1 showed more 
resistance to trypsin in the presence of ligand compared to control. Therefore from these 
interaction experiments we concluded that phloridzin is interacting with hFGF-1 and 
protecting it against thermal denaturation and trypsin digestion. 
           In order to find the exact sites of binding and stoichiometry of binding between 
phloridzin and hFGF-1, we performed 1H–15N HSQC NMR, from the results we found 
that Gly34, Tyr61, Tyr70, Gly77, Ala 109, Asp 146 and Trp 129 are putative binding 
sites of phloridzin on hFGF-1.  
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6. FUTURE WORK 
            Phloridzin and hFGF-1 interaction can be studied further by using iso thermal 
titration calorimetry (ITC), which will give useful information about dissociation 
constant and enthalpy change of the interaction. The information form ITC is very useful 
in order to compare the affinity of hFGF-1 for binding with phloridzin and heparin. In 
addition, In vivo experimental studies on hFGF-1 interaction with phloridzin will give 
information about possibility of interaction under physiological conditions.  Therefore, 
the future work will give more insight into the interaction between and phloridzin and 
hFGF-1, results will give further leads in to anticancer activity of phloridzin.   
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